VivoSim Labs, Inc. (NASDAQ: VIVS), a biotechnology services company specializing in non-animal drug testing methods, has announced a private placement agreement to raise approximately $4 million from a single healthcare-focused institutional investor. The transaction, disclosed in a press release, involves the sale of 4,705,883 shares of common stock or common stock equivalents, along with accompanying warrants, at a combined price of $0.85 per share. The warrants are exercisable following shareholder approval and expire five years after their initial exercise date, with an exercise price of $0.85 per share. Additionally, subject to shareholder approval, the company agreed to amend certain existing May 2024 warrants, reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, pending customary conditions. VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities are being offered in a private placement exempt from Securities Act registration requirements, and the company has committed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued. For more details, the full press release is available at https://ibn.fm/7Ov0B.
This capital infusion comes at a pivotal time for VivoSim, which positions itself as a key player in the shift toward non-animal testing methodologies. The company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models, which are three-dimensional human tissue models of liver and intestine. VivoSim anticipates accelerated adoption of these models following the U.S. Food and Drug Administration (FDA) Roadmap to refine animal testing requirements in favor of non-animal NAM methods. As the FDA pushes for reduced reliance on animal testing, VivoSim’s technology could become increasingly important for pharmaceutical companies seeking to evaluate drug candidates more efficiently and ethically.
The significance of this funding extends beyond VivoSim’s immediate financial needs. It signals investor confidence in the company’s approach and its potential to capitalize on regulatory trends. The warrants, with a five-year term, provide a mechanism for additional capital if exercised, while the reduction of the exercise price on existing warrants from $9.60 to $0.85 aligns incentives for warrant holders. The company’s focus on working capital and general corporate purposes suggests it may be preparing to scale operations, expand its model offerings, or invest in sales and marketing to capture market share.
VivoSim Labs, based in San Diego, CA, is a pharmaceutical and biotechnology services company. More information about the company is available on its website at https://vivosim.ai/. The announcement was disseminated by MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. For more details on MissionIR and its services, visit https://www.MissionIR.com.
